Cardiovascular consequences of metabolic syndrome
- PMID: 28130064
- PMCID: PMC5393930
- DOI: 10.1016/j.trsl.2017.01.001
Cardiovascular consequences of metabolic syndrome
Abstract
The metabolic syndrome (MetS) is defined as the concurrence of obesity-associated cardiovascular risk factors including abdominal obesity, impaired glucose tolerance, hypertriglyceridemia, decreased HDL cholesterol, and/or hypertension. Earlier conceptualizations of the MetS focused on insulin resistance as a core feature, and it is clearly coincident with the above list of features. Each component of the MetS is an independent risk factor for cardiovascular disease and the combination of these risk factors elevates rates and severity of cardiovascular disease, related to a spectrum of cardiovascular conditions including microvascular dysfunction, coronary atherosclerosis and calcification, cardiac dysfunction, myocardial infarction, and heart failure. While advances in understanding the etiology and consequences of this complex disorder have been made, the underlying pathophysiological mechanisms remain incompletely understood, and it is unclear how these concurrent risk factors conspire to produce the variety of obesity-associated adverse cardiovascular diseases. In this review, we highlight current knowledge regarding the pathophysiological consequences of obesity and the MetS on cardiovascular function and disease, including considerations of potential physiological and molecular mechanisms that may contribute to these adverse outcomes.
Copyright © 2017 Elsevier Inc. All rights reserved.
Figures

Similar articles
-
Metabolic syndrome, glucose tolerance categories and the cardiovascular risk in Spanish population.Diabetes Res Clin Pract. 2016 Apr;114:23-31. doi: 10.1016/j.diabres.2016.02.003. Epub 2016 Feb 21. Diabetes Res Clin Pract. 2016. PMID: 27103365 Clinical Trial.
-
Determinants of increased cardiovascular disease in obesity and metabolic syndrome.Curr Med Chem. 2011;18(34):5267-80. doi: 10.2174/092986711798184299. Curr Med Chem. 2011. PMID: 22087824 Review.
-
The effect of increasing body mass index on cardio-metabolic risk and biomarkers of oxidative stress and inflammation in nascent metabolic syndrome.J Diabetes Complications. 2017 May;31(5):810-813. doi: 10.1016/j.jdiacomp.2017.02.010. Epub 2017 Feb 27. J Diabetes Complications. 2017. PMID: 28285929
-
Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome.Antioxid Redox Signal. 2011 Oct 1;15(7):1911-26. doi: 10.1089/ars.2010.3739. Epub 2011 May 6. Antioxid Redox Signal. 2011. PMID: 21126197 Review.
-
Operative risk factors in the metabolic syndrome: is it lipids and high blood pressure or are there direct vascular effects of insulin resistance and obesity?Curr Cardiol Rep. 2006 Nov;8(6):427-32. doi: 10.1007/s11886-006-0100-4. Curr Cardiol Rep. 2006. PMID: 17059794 Review.
Cited by
-
Susceptibility and Severity of Viral Infections in Obesity: Lessons from Influenza to COVID-19. Does Leptin Play a Role?Int J Mol Sci. 2021 Mar 20;22(6):3183. doi: 10.3390/ijms22063183. Int J Mol Sci. 2021. PMID: 33804765 Free PMC article. Review.
-
The Metabolic Syndrome, a Human Disease.Int J Mol Sci. 2024 Feb 13;25(4):2251. doi: 10.3390/ijms25042251. Int J Mol Sci. 2024. PMID: 38396928 Free PMC article. Review.
-
Robust effect of metabolic syndrome on major metabolic pathways in the myocardium.PLoS One. 2019 Dec 2;14(12):e0225857. doi: 10.1371/journal.pone.0225857. eCollection 2019. PLoS One. 2019. PMID: 31790488 Free PMC article.
-
Validation of Surrogate Anthropometric Indices in Older Adults: What Is the Best Indicator of High Cardiometabolic Risk Factor Clustering?Nutrients. 2019 Jul 24;11(8):1701. doi: 10.3390/nu11081701. Nutrients. 2019. PMID: 31344803 Free PMC article.
-
Therapeutic Apheresis in Metabolic Syndrome.Immunol Endocr Metab Agents Med Chem. 2018 May;18(1):38-54. doi: 10.2174/1871522218666180608114536. Immunol Endocr Metab Agents Med Chem. 2018. PMID: 30369968 Free PMC article.
References
-
- Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni's 'De sedibus et causis morborum per anatomen indagata'. Int J Obes Relat Metab Disord. 2003;27(4):534–5. - PubMed
-
- Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens. 2006;24(4):621–6. - PubMed
-
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607. - PubMed
-
- Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Despres JP, Ndumele CE, et al. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol. 2015;66(9):1050–67. - PubMed
-
- Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report. 2009;(13):1–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical